Export of Drugs

1121. CHOWDHARY RAM SEWAK:

DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of COMMERCE be pleased to state:

(a) What are the names of the producers who exported Norfloxacin, Danazol, Vincrestine and Vinblastine during the last two years, yearwise;

(b) what are the names of the countries to which these drugs were exported, the quantity exported to each country by each party; and

(c) what was the foreign exchange amount earned in such exports?

THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE (SHRI P. R. DAS MUNSHI): (a) to (c) A statement is attached [*See* Appendix CL, Annexure No. 54].

Requirement and production of Norfloxacin and Danazol

1122. SHRI ASHOK NATH VERMA:

DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of COMMERCE be pleased to refer to the answer to Unstarred Question 2555 given in the Rajya Sabha on the 16th March, 1989 and state:

(a) whether it is a fact that Norfloxacin & Danazol are being produced from basic stages with indigenously developed technologies;

(b) whether it is also a fact that the capacities created and indigenous production of these drugs is much more than the requirement of the country;

(c) whether it is also a fact that his Ministry has not examined all the factors in respect to these drugs;

(d) what are the specific reasons for allowing the import of these drugs and wasting valuable foreign exchange;

(e) whether it is also a fact that such an attitude of his Ministry is against the objecive of the Government ot achieve self-sufficiency; and

(f) if so, what corrective steps are being taken in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE (SHRI P. R. DAS MUNSHI): (a) and (b) The production of Norfloxacin has been started by M|s Ranbaxy during the last six months. Danazol is produced by M|s. Tamil Nadu Dadha Pharmaceuticals and M|s. Cipla Ltd. The production by M/s. Tamil Nadu Dadha was 127 tonnes during 1987 while M|s. Cipla Limited did not report any production during 1987.

(c) to (f) Import of these drugs is allowed under OGL keeping in view the indigenous production *vis-a-vis* demand, etc., with a view to avoid short supply of these life saving drugs.

Import of vincrestine and vinblastine injections

1123. DR. (SHRIMATI) SAROJINI MAHISHI:

SHRI CHITTA BASU:

Will the Minister of COMMERCE be pleased to refer to the answer to Unstarred Question 2536 given in the Rajya Sabha on the 16th March, 1989 and state:

(a) whether it is a fact that indigenous capacity is around ten times of the country's requirement of Vincrestine and Vinblastine Injections;

(b) whether it is also a fact that the quality of indigenous production has been accepted throughout the world including USA, UK and other developed countries;

(c) whether it is also a fact that the indigenous prices are less than the imported prices;

(d) whether it is also a fact that his Ministry is neither monitoring the production nor the export, quality, prices and demand of the country;

(e) whether his Ministry has collected such information from concerned departments;

(f) if so, the details thereof;

(g) whether it is also a fact that on one side indigenous capacity is lying idle and on the other valuable foreign exchange is wasted; and

(h) if so, what corrective steps are being taken in the matter?

THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE (SHRI P. R. DAS MUNSHI): (a) The following capacities have been granted for these drugs:—

Viiblastine	8.5 Kgs. (capacity)
Vincrestine	5.9 Kgs. (capacity)

These are new drugs and their demand and production are, therefore, yet to be established.

(b) Acceptance of the quality of Indian products (drugs) by other countries is not monitored.

(c) These drugs are price-decontrolled and therefore, details are not available.

(d) to (h) Vincrestine Sulphate (a bulk drug) is being produced by M|s.. Cipla and M|s. Infar India Ltd. While M|s. Cipla have not furnished production returns for the year 1987-88, the production reported by M|s Infar India Limited during 1987 was only for one month *i.e.*, December, 1987 which was to the tune of 9,3 gms. only. The import of these drugs is allowed under Open General Licence keeping in view the indigenous production *vis-a-vis* demand, etc., and with a view to avoid any shortage of these life saving drugs.

Import of Danazol

1124. SHRI DHARANIDHAR BASUMATARI:

DR. (SHRIMATI) SAROJINI MAHISHI:

Will the Minister of COMMERCE be pleased to refer to the answer to Unstarred Question 2539 given in the Rajya Sabha on the 16th March, 1989 and state:

(a) whether it is a fact that the production of Danazol in the country is more than five tonnes;

(b) whether it is also a fect that the indigenous price is less than the imported price;

(c) whether it is also a fact that indigenous Danazol is exported to USA, UK and other developed countries;

(d) whether it is also a fact that the quality of Indian Danazol is accepted all over the world;

(e) whether it is also a fact that his Ministry is neither monitoring nor compiling the information of import, export, production quality, price, unutilisation capacity, availability and demand; and

(f) if so, the reasons for allowing imports of Danazol under OGL and discouraging indigenous production and wasting valuable foreign exchange?

THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE (SHRI P. R. DAS MUNSHI): (a) Yes, Sir.

(b) Details of the price are not available as this is a price decontrolled drug.

(c) to (f) Export of drugs is allowed on decontrolled basis and without the requirement of exrort licence, Danazol is not separately classified in the Indian trade classification REV-2 on the basis of which foreign trade statistics of India are compiled. Hence data on import|export of Danazol is not available.

Import of Danazol is allowed under OGL keeping in view the indigenous production *vis-a-vis* demand, availability of technology etc., and with a view to avoid short supply of this life saving drug.